GLP-1 and Mental Health | CNP Research Library (Adult Population)

The CNP GLP-1 & Mental Health Research Category features studies examining how Glucagon-like peptide 1 receptor agonist (GLP-1RA) used for diabetes and obesity may affect mood, quality of life, emotional well-being, and eating behaviors in individuals undergoing treatment. This category includes research investigating psychiatric outcomes, such as changes in symptoms of depression, anxiety, and eating control, both positive and negative, following GLP-1 therapy. It also highlights studies on these agents’ potential roles in treating overlapping mental health and eating disorders, as well as their psychiatric safety profile and the need for ongoing clinical attention. Become a CNP Library Member to learn more.

CNP Library Membership

RESEARCH SUMMARIES

Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans

Use of Glucagon-Like Peptide 1 receptor agonists and the associated risk of hospitalization in Bipolar Disorder, from a nationwide cohort, 2009–2024

The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis

Nutritional, functional, and psychological considerations for incretin-based therapies in adults—an EASO, EFAD, and ECPO Consensus Statement

Beyond weight loss: GLP-1 usage and appetite regulation in the context of eating disorders and psychosocial processes

The impact of novel medications for obesity on weight stigma and societal attitudes: A narrative review

What is food noise? A conceptual model of food cue reactivity

Highway to the danger zone? A cautionary account that GLP-1 receptor agonists may be too effective for unmonitored weight loss

Association between GLP-1 receptor agonist use and worsening mental illness in people with depression and anxiety in Sweden: A national cohort study